Ascendia

  MARKET NEWS

Adragos Pharma Acquires Leading Swiss Sterile Fill-Finish Expert
Kanglin Biotechnology Announces $20-Million Financing to Advance the Development of Gene Therapies
IMUNON Announces Results From its End-of-Phase 2 Meeting With the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
Tenaya Therapeutics Doses First Patient in Phase 1b Clinical Trial for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
Bormioli Pharma Invents The Open & Collaborative Innovation Platform for the Pharmaceutical Packaging of the Future
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
UMDF & Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease
BriaCell Announces First Patient Dosed With Bria-OTS in Metastatic Breast Cancer Study
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV & Malaria Using C1 Platform Technology

  EXPERT CONTENT & RESOURCES

 

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Private: Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

DRUG-DEVICE DEVELOPMENT - Exploring the Complexities of Drug-Device Combination Products

Jeremy Guo, Senior Vice President at WuXi Biologics, and colleagues explain that many factors need to be taken into account when producing a Drug-Device Combination Product from development testing to fill/finish and assembly.

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

MediWound Ltd.:  Developing a New Class of Biologic Enzymatic Therapeutic  Products to Debride Wounds

Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.

  FEATURED EDITORIAL

  COMPANY PROFILE

As Part of Terumo Medical Care Solutions, the Pharmaceutical Solutions Division develops patient-oriented parenteral delivery solutions for therapeutic performance and safety. Globally trusted for quality and precision, we offer pharmaceutical and medical device manufacturers around the world comprehensive product design and development services. We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies, including CDMO services for all parenteral applications. Click here for more.

  WHITEPAPERS & WEBINARS

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Mucoadhesion Matters

And so does your choice of mucoadhesive polymer.

This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism …

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 4 – Inhalation Delivery
December 11 – ODT/Fast Dissolve